Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

Journal of the American Academy of Dermatology

Volumn 74, Issue 3, 2016, Pages 455-461.e1

  Hwang, Shelley Ji Eun ^a,b   Carlos, Giuliana ^a,b   Wakade, Deepal ^a,b   Byth, Karen ^a,b   Kong, Benjamin Y ^a   Chou, Shaun ^a   Carlino, Matteo S ^a,b,c   Kefford, Richard ^a,c   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

anti programmed cell death 1; eczema; immune reaction; immunotherapy; lichenoid reaction; metastatic melanoma; vitiligo

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACTINIC KERATOSIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BASAL CELL CARCINOMA; BULLOUS PEMPHIGOID; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER THERAPY; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; CYST; DARIER DISEASE; DERMATOLOGY; DISEASE ASSOCIATION; DRUG ERUPTION; ECZEMA; FEMALE; FOLLICULITIS; HEMANGIOMA; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HYPOPIGMENTED NEVUS; LENTIGO; LICHEN PLANUS; LICHENOID; LIVEDO RETICULARIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MELANOMA; METASTATIC MELANOMA; NEVUS; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PSORIASIS; ROSACEA; SEBOPSORIASIS; SEBORRHEIC KERATOSIS; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; TINEA; VITILIGO; WOUND; APOPTOSIS; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG ERUPTIONS; LICHENOID ERUPTION; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SKIN NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG ERUPTIONS; ECZEMA; FEMALE; HUMANS; LICHENOID ERUPTIONS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; VITILIGO; YOUNG ADULT;

EID: 84958150171     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.10.029     Document Type: Article

References (27)

1. M. Mackiewicz-Wysocka, J. Zolnierek, and P.J. Wysocki New therapeutic options in systemic treatment of advanced cutaneous melanoma Expert Opin Investig Drugs 22 2 2013 181 190
2. A. Mamalis, M. Garcha, and J. Jagdeo Targeting the PD-1 pathway: a promising future for the treatment of melanoma Arch Dermatol Res 306 6 2014 511 519
3. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454
4. S. Stadler, K. Weina, C. Gebhardt, and J. Utikal New therapeutic options for advanced non-resectable malignant melanoma Adv Med Sci 60 1 2014 83 88
5. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
6. C. Robert, J. Schachter, G.V. Long, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
7. C. Robert, G.V. Long, B. Brady, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 4 2015 320 330
8. Weber J, Gibney G, Yu B, et al. Moffitt Cancer Center, Tampa, FL. Survival, biomarker, and toxicity analysis of nivolumab in patients that progressed on ipilimumab. Poster session presented at: Melanoma/Skin Cancers 51st American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago, IL.
9. M. Hao, F. Song, X. Du, and et al. Advances in targeted therapy for unresectable melanoma: new drugs and combinations Cancer Lett 359 1 2015 1 8
10. L. Min, and F.S. Hodi Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis Cancer Immunol Res 2 1 2014 15 18
11. O. Hamid, C. Robert, A. Daud, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2 2013 134 144
12. E.J. Lipson, W.H. Sharfman, C.G. Drake, and et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2 2013 462 468
13. R.W. Joseph, M. Cappel, B. Goedjen, and et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy Cancer Immunol Res 3 1 2015 18 22
14. M. Sanlorenzo, I. Vujic, A. Daud, and et al. Pembrolizumab cutaneous adverse events and their association with disease progression JAMA Dermatol 151 2015 1206 1212
15. Weber J, Antonia S, Topalian S, et al. Safety profile of nivolumab in patients with advanced melanoma: a pooled analysis. Poster session presented at: Melanoma/Skin Cancers 51st American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago, IL.
16. Freeman-Keller M WJ. Nivolumab in resected and unresectable melanoma: immune-related adverse events and association with survival outcomes. Poster session presented at Melanoma/Skin Cancers 51st American Society of Clinical Oncology Annual Meeting; May 29-June 2, 2015; Chicago, IL.
17. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 26 2012 2455 2465
18. R.J. Sullivan, and K.T. Flaherty Pembrolizumab for treatment of patients with advanced or unresectable melanoma Clin Cancer Res 21 2015 2892 2897
19. O. Hamid, and R.D. Carvajal Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy Expert Opin Biol Ther 13 6 2013 847 861
20. A. Swaika, W.A. Hammond, and R.W. Joseph Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy Mol Immunol 67 2 Pt A 2015 4 17
21. J.B. Macdonald, B. Macdonald, L.E. Golitz, P. LoRusso, and A. Sekulic Cutaneous adverse effects of targeted therapies; part II: inhibitors of intracellular molecular signaling pathways J Am Acad Dermatol 72 2 2015 221 236 quiz 37-38
22. T. Okazaki, and J. Wang PD-1/PD-L pathway and autoimmunity Autoimmunity 38 5 2005 353 357
23. R.M. Anforth, T.C. Blumetti, R.F. Kefford, and et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma Br J Dermatol 167 5 2012 1153 1160
24. D.P. Zandberg, and S.E. Strome The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck Oral Oncol 50 7 2014 627 632
25. G. Carlos, R. Anforth, A. Clements, and et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma JAMA Dermatol 151 2015 1103 1109
26. B. Merelli, D. Massi, L. Cattaneo, and M. Mandala Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities Crit Rev Oncol Hematol 89 1 2014 140 165
27. P. Armitage, G. Berry, and J. Matthews Statistical methods in medical research 4th ed. 2002 Blackwell Science Oxford